Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.76 |
| ▸ | GLP1R | P43220 | 8/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.65 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.62 |
| ▸ | CASP2 | P42575 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25542989 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL25542969 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL13855525 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL25542983 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL7041680 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL542980 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL14937066 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL14937349 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL14937344 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL25542900 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8647613-B2 | Drug carrier | JCR PHARMACEUTICALS CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20130123485-A1 | CATIONIC LIPIDS, METHODS FOR PREPARING THE SAME, AND DELIVERY SYSTEMS HAVING ABILITY TO TRANSITION INTO CELLS COMPRISING THE SAME | BIOPOLYMED INC. (KR) | 2013-05-16 | — | — | US | disclosed |
| US-20090136443-A1 | Drug Carrier | OXGENIX CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123485-A1 | CATIONIC LIPIDS, METHODS FOR PREPARING THE SAME, AND DELIVERY SYSTEMS HAVING ABILITY TO TRANSITION INTO CELLS COMPRISING THE SAME | SGMS1, SGMS2, NPC1L1 | NOD1 3910/4885GLP1R 3581/4885EPHX2 2411/4885 |
| US-20090136443-A1 | Drug Carrier | ABCB11, SLC47A1, SLC47A2 | NOD1 2645/4885GLP1R 3255/4885EPHX2 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.